Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
NCT ID | NCT04781192 |
Title | The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers |
Recruitment | Recruiting |
Gender | both |
Phase | Phase Ib/II |
Variant Requirements | No |
Sponsors | University of Kansas Medical Center |
Indications | |
Therapies | |
Age Groups: | adult | senior |
Covered Countries | USA |